A New Name in Weight-Loss Drugs

Motley Fool Money

Novo Nordisk and Eli Lilly have soared on GLP-1 weight-loss drugs – now Hims & Hers is trying to get in on the action with a more available and affordable option.


(00:21) Asit Sharma and Dylan Lewis discuss:


- Hims & Hers getting into the business of GLP-1 weight loss injections and what the compound market means for Novo Nordisk and Eli Lilly.

- A sneaky company that’s another winner in the weight-loss market.

- Wix’s successful pivot to a free-cash-flow orientation, and how the AI wave is pushing the company forward.


(14:52) Gym stocks haven’t worked out for most investors, Ricky Mulvey caught up with Motley Fool analyst Sanmeet Deo to find out why he has cooled on one fast-growing gym franchisor and a space in fitness that is investable.


Companies discussed: HIMS, NVO, MCK, LLY, Wix


Host: Dylan Lewis

Guests: Asit Sharma, Ricky Mulvey, Mary Long

Producer: Ricky Mulvey

Engineers: Dan Boyd


Learn more about your ad choices. Visit megaphone.fm/adchoices

2024-05-20 26 min

Available Results

Generated results are saved to your library for reuse and search.

No generated results are available for this episode yet.

Transcript

No transcript is available for this episode yet.
Sign in to generate a transcript for review.
Sign in

Chapters

No chapters available.